KIT and metastatic neoplasm: Various studies have demonstrated c-kit expression in renal tumors which could be targeted for treatment using imatinib mesylate.[4] This could be more useful in the treatment of aggressive and metastatic tumors which do not have any specific and effective treatment since imatinib mesylate is a relatively non-toxic therapeutic agent.